# A Clinical Study of MIL95 in Advanced Malignancies.

> **NCT04651348** · PHASE1 · RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 58 (estimated)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** Recombinant Humanized Monoclonal Antibody MIL95

## Key facts

- **NCT ID:** NCT04651348
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-04
- **Primary completion:** 2022-12-08
- **Final completion:** 2024-11
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04651348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04651348, "A Clinical Study of MIL95 in Advanced Malignancies.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04651348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*